Cencora, Inc. (NYSE:COR) Shares Sold by Hills Bank & Trust Co

Hills Bank & Trust Co reduced its position in Cencora, Inc. (NYSE:COR) by 1.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,956 shares of the company’s stock after selling 94 shares during the period. Hills Bank & Trust Co’s holdings in Cencora were worth $1,566,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of COR. FORVIS Wealth Advisors LLC acquired a new position in shares of Cencora in the 1st quarter valued at about $736,000. Maryland State Retirement & Pension System acquired a new position in shares of Cencora in the 1st quarter valued at about $3,133,000. Retirement Systems of Alabama acquired a new position in shares of Cencora in the 1st quarter valued at about $8,880,000. J.W. Cole Advisors Inc. purchased a new stake in shares of Cencora during the 1st quarter valued at about $906,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Cencora during the 1st quarter valued at about $1,479,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE COR opened at $233.00 on Friday. Cencora, Inc. has a twelve month low of $184.00 and a twelve month high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The company has a market capitalization of $45.91 billion, a price-to-earnings ratio of 24.76, a price-to-earnings-growth ratio of 1.46 and a beta of 0.44. The business has a 50 day simple moving average of $231.46 and a 200-day simple moving average of $230.71.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the previous year, the business earned $2.92 EPS. The business’s quarterly revenue was up 10.8% on a year-over-year basis. As a group, equities research analysts expect that Cencora, Inc. will post 13.64 earnings per share for the current year.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on COR. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners dropped their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. JPMorgan Chase & Co. raised their target price on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Finally, Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.